Takehide Iwasa

tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan.

Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan.

Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities.